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Abstract 
Background: Mesenchymal stromal cells (MSCs) have an inherent migratory capacity towards tumor tissue in vivo. 
With the future objective to quantify the tumor homing efficacy of MSCs, as first step in this direction we investigated 
the use of inorganic nanoparticles (NPs), in particular ca. 4 nm-sized Au NPs, for MSC labeling. Time dependent uptake 
efficiencies of NPs at different exposure concentrations and times were determined via inductively coupled plasma 
mass spectrometry (ICP-MS).
Results: The labeling efficiency of the MSCs was determined in terms of the amount of exocytosed NPs versus the 
amount of initially endocytosed NPs, demonstrating that at high concentrations the internalized Au NPs were exo-
cytosed over time, leading to continuous exhaustion. While exposure to NPs did not significantly impair cell viability 
or expression of surface markers, even at high dose levels, MSCs were significantly affected in their proliferation and 
migration potential. These results demonstrate that proliferation or migration assays are more suitable to evaluate 
whether labeling of MSCs with certain amounts of NPs exerts distress on cells. However, despite optimized conditions 
the labeling efficiency varied considerably in MSC lots from different donors, indicating cell specific loading capacities 
for NPs. Finally, we determined the detection limits of Au NP-labeled MSCs within murine tissue employing ICP-MS 
and demonstrate the distribution and homing of NP labeled MSCs in vivo.
Conclusion: Although large amounts of NPs improve contrast for imaging, duration and extend of labeling needs to 
be adjusted carefully to avoid functional deficits in MSCs. We established an optimized labeling strategy for human 
MSCs with Au NPs that preserves their migratory capacity in vivo.
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Background
Mesenchymal stromal cells (MSCs) exhibit a high ex vivo 
expansion capacity and have already entered the clinic 
as cellular products for various applications [1, 2]. They 
possess anti-inflammatory and regenerative potential, 
and migrate into sites of inflammation, tissue repair, and 
neoplasia [3–5]. Due to their properties and safety, they 
are considered as a promising tool in regenerative medi-
cine and oncology. About 200 clinical phase I/II and III 
studies revealed no side effects, even in allogenic set-
tings [6]. In oncology, new therapeutic concepts envision 
e.g. genetically modified MSCs as a vehicle to selectively 
deliver anti-tumorigenic proteins or compounds to neo-
plastic tissue [7]. The efficacy of these approaches, as 
well as the extent of side effects, is directly linked to the 
potential of MSCs to accumulate in tumors after systemic 
administration. In the context of regenerative medicine, 
MSCs are used a promising therapeutic approach to 
repopulate extracellular matrixes, with the function to 
repair and reconstruct complex tissues. Thus, the clini-
cal use of MSCs has overcome its infancy steps [8]. Still, 
many details remain to be unraveled. This involves for 
example the mechanisms of homing, and in particular 
also the in vivo fate of MSCs. This circumstance evokes 
the necessity for a noninvasive in  vivo MSC tracking 
method that does not influence their biological proper-
ties and cellular function, is highly specific to the target 
cells, is biocompatible, safe and nontoxic, and allows for 
quantification of low MSC numbers in invaded tissue [9]. 
Stem cell-tracking methods being currently used rely on 
labeling the cells with fluorescent molecules for optical 
imaging, radionuclides for positron or gamma photon 
emission tomography (PET), or labeling with certain con-
trast agents, such us exogenous elements, which either 
allow visualization by magnetic resonance imaging (MRI) 
or can be detected by mass spectrometry [10–15]. In the 
first case the application is limited to small animals or 
intraoperative use, due to light adsorption in thick tis-
sue. The second approach requires extensive preparation 
of MSCs and handling of radioactive materials. In the 
third case, when using mass spectrometry as detection 
method, tissue decomposition prior to measurements is 
needed. All methods are limited in sensitivity by non-suf-
ficient cell labeling efficiency, or require extensive tissue 
treatment for further imaging and detection. Combined 
with low stem cell homing, efficiency revised labeling 
considerations are needed.
Non-invasive imaging of MSCs after labeling with 
inorganic colloidal nanoparticles (NPs) is a promising 
tool that allows for recording distributions and the long-
term tracking of the MSCs after systemic application 
{Huang, 2014 #32200; Skopalik, 2014 #32201; Schmidtke-
Schrezenmeier, 2011 #32202; Betzer, 2015 #32883; Meir, 
2015 #32885}. In comparison to organic molecules, inor-
ganic NPs may allow for higher contrast in certain imag-
ing techniques, such as magnetic resonance imaging 
(MRI) and computer tomography (CT). In MRI,  FeOx 
NPs have been demonstrated to provide good contrast in 
transverse relaxation time  (T2)-based imaging [16, 17]. In 
CT, the best contrast is obtained for elements with high 
atomic number. Thus, Au NPs are good candidates for 
labeling strategies [18, 19]. For our study we employed 
4.25 (±0.88) nm Au NPs coated with the amphiphilic 
polymer poly (isobutylene-alt-maleic anhydride) modi-
fied with dodecylamine (PMA). The NPs were purified 
via gel electrophoresis or ultracentrifugation, and sub-
jected to full characterization as previously reported [20]. 
This included UV/Vis absorption spectroscopy, transmis-
sion electron microscopy (TEM), and dynamic light scat-
tering (DLS). NPs are in general readily endocytosed by 
cells [21, 22], and thus, labeling of MSCs in principle is 
straightforward. Upon cell division, the NPs are passed to 
the two daughter cells [23].
However, while in principle, the concept seams easily 
to be conducted, labeling of MSCs with NPs has to be 
performed under a delicate balance. From the imaging 
point of view, more NPs inside each MSC would relate 
directly to better contrast in imaging. On the other hand, 
it is reasonable to reduce the amount of NPs inside each 
MSC as much as possible, in order to avoid potential 
cytotoxic effects. Thus, labeling conditions need to be 
carefully optimized. Au NPs are promising candidates, as 
their biocompatibility at low doses is well-accepted [24]. 
Gold has been used for example as clinical therapeutic 
in patients with severe rheumatologic disorder for many 
years, with well-known safety profit and limited side 
effects [25]. Gold is usually not present in living organ-
isms and thus, tracing of Au NPs by mass spectrometry 
benefits from low background signals, in contrast to 
 FeOx NPs, as there is a significant level of endogenous/
constitutive iron. Recent studies have shown that Au 
NPs at least partially fulfill basic requirements for effi-
cient long term labeling of MSCs, i.e. long term stability, 
low cytotoxicity, and most importantly, no interference 
with cellular functioning. Ricles et al. have demonstrated 
that lysine coated Au NPs of hydrodynamic diameters of 
around 50 nm do not interfere with differentiation [26]. 
Long term tracking for a period of 2 weeks seems feasi-
ble, due to high retention times and low cytotoxicity. In 
contrast with these findings, some studies revealed a neg-
ative effect of Au NPs on certain cellular functions such 
as proliferation [27, 28]. In addition the morphology of 
subcellular structures seems to be disturbed depending 
on the applied dose [29].
To further assess the biocompatibility and suitability 
of Au NPs for MSC tracking, we investigated cellular 
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responses to Au NP labeling in MSC derived humans 
(hMSCs), such as uptake, cytotoxicity, proliferation, 
migration, morphology, immunophenotype, and in  vivo 
biodistribution. For MSC detection via mass spectrome-
try we elucidated the detection sensitivity by quantifying 
the required number of labeled cells to be able to prove 
MSC presence in a population of cancer cells.
Results
Au NPs are readily incorporated by MSCs
We monitored the incorporation of Au NPs into MSCs 
in a dose- and time-dependent manner, cf. Fig. 1. In the 
present study, ca. 4 nm core-sized Au NPs and exposure 
concentrations ranging from  cNP  =  1 to 100  nM were 
used [30]. The uptake was quantified by determination 
of elemental Au levels inside cells via ICP-MS (cf. Fig. 1). 
In general the amount of internalized NPs increased over 
time, whereby after long exposure times (>24 h) and high 
NP concentrations saturation effects could be observed, 
cf. Fig. 1. The data shown in Fig. 1 allow for calculating 
the average number  NNP of Au NPs, which were internal-
ized by each cell as  NNP = (mAu/MAu)·NA, with  mAu being 
the mass of elemental Au inside each cell as detected with 
ICP-MS (cf. Fig. 1),  MAu = 196 g/mol the molar mass of 
Au, and Avogadro’s constant  NA = 6.02·1023/mol. In case 
of exposure to  cNP = 10 nM Au NPs for 24 h this results 
in  NNP ≈ 4·105 NPs per cell, approximating each NP as a 
sphere of core diameter  dc = 4.2 nm (i.e. ca. 4 nm) and 
constant density ignoring the extent in volume due to the 
polymer coating. For comparison, at  cNP = 10 nM around 
6·1012 NPs are contained in 1 mL of growth medium. In 
fact, only a small fraction of NPs present in the medium 
was actually incorporated by cells, as known also from 
previous studies [31]. The classical uptake pathway of 
NPs by cells is endocytosis [22], and internalized NPs are 
enriched in intracellular vesicles. Therefore, NP excretion 
was investigated by measuring the increasing Au content 
in the extracellular medium 24 or 48 h after labeling, as 
depicted in Fig. 2. The data demonstrate that with rising 
NP concentrations the excretion via exocytosis is also 
increasing, which takes place largely within the first 24 h. 
Note that ICP-MS can not distinguish between Au NPs 
just adherent to the outer cell membrane and Au NPs 
that have been in fact endocytosed. There are methods 
available which allow for separating both populations [32, 
33]. However, we did not apply this analysis, as it would 
not be relevant for the in vivo studies, as discussed in the 
respective paragraph.
Functional impact of Au NP labeling on MSCs
These observations prompted us to investigate the 
biocompatibility of the ca. 4  nm Au NPs. Cell viabil-
ity after exposure to Au NPs was assessed employ-
ing the resazurin (AlamarBlue) assay [34, 35]. The data 
shown in Fig. 3 indicate that the cell viability of human 
MSCs exposed to NPs for 24 and 48 h was not strongly 
affected. However, a trend for a decrease of cell viability 
was observed at high NP concentrations  (cNP  >  50  nM) 
at longer exposure times (72 h). Because cell viability as 
measured by the resazurin assay has limited sensitivity as 
indicator for probing effects of NPs on MSCs, we addi-
tionally carried out a NP-concentration dependent prolif-
eration assay, cf. Fig. 4. Relative cellular proliferation was 
Fig. 1 Quantitative determination of uptake of Au NPs by MSCs. 
hMSCs were incubated with Au NPs (ca. 4 nm core diameter) with 
different concentrations  (cNP = 2–100 nM) for a range of times (5, 24, 
48 h). After washing, the mass  mAu of intracellular Au was determined 
by ICP-MS and was normalized to the initial number of cells. Results 
are presented as mean value ± relative error (derived from propa-
gation of standard deviation (SD) from at least three independent 
experiments using cells from different donors
Fig. 2 Endocytic uptake and exocytosis of Au NPs by MSCs. MSCs 
were exposed to Au NPs (ca. 4 nm core diameter) at the indicated 
doses  cNP for 24 or 48 h. After washing off residual NPs from the 
medium and the outer cell membrane, i.e. NPs which had not been 
internalized by the MSCs, culturing was continued in fresh growth 
medium for 24 or 48 h. Then, the amount of intracellular Au NP  mAu 
(i.e. amount of elemental Au inside the cell pellet) and exocytozed 
Au NPs (i.e. amount of elemental Au in the medium)  mAu,exo were 
determined by ICP-MS. Finally, the fraction of exocytosed Au NPs 
was determined as  mAu,exo/(mAu,exo + mAu) = mAu,exo/mAu,tot. For cells 
labeled with  cNP = 2 nM (°) the Au content in the cell medium was 
below the detection limit
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significantly reduced for  cNP = 50 nM. In fact already at 
very low NP doses of 2 nM, there is a tendency of con-
centration-dependent reduction of proliferation. Moreo-
ver, migratory functioning is of particular importance for 
in vivo homing of MSC in tumor tissue. In several studies 
MSCs were used for homing and tracking experiments 
[36]. As depicted in Fig.  4 we demonstrate that cellular 
migration through a porous membrane [37] was affected 
in case cells have incorporated NPs. Our data suggest 
a dose dependent inhibitory effect on the migration 
capacity of MSCs labeled with Au NPs. A significant neg-
ative effect was already visible for  cNP = 50 nM. Based on 
our data, we identified the least tolerable dose of ca. 4 nm 
diameter Au NPs exposed to MSC for 48 h to be around 
10  nM. In order to probe whether labeling of MSCs 
under these conditions affects the immunophenotype 
of MSCs, expression of surface markers was determined 
by flow cytometric analysis upon exposure to NPs. Our 
results showed that Au NP-labeled MSCs maintained 
their characteristic immunophenotype, as determined by 
expression analysis of CD73, CD90 and CD105. MSC did 
not express CD14, CD19, CD34, CD45, and HLA-DR as 
shown in Fig. 5. The immunophenotype of MSCs labeled 
under these conditions is in accordance with the con-
sensus criteria [38]. This is in line with results obtained 
by Mailänder et  al., who showed no impact on lineage 
markers and differentiation [39] upon NP-labeling of 
MSCs. In this way, at reasonable Au NP concentrations 
(i.e. 10 nM for ca. 4  nm Au NPs), the NP labeling does 
not interfere with the immunophenotype, and does not 
cause long-term cytotoxicity. However, our data reveal 
onset of negative effects on proliferation and migration 
potential already at these concentrations. Taken together 
the amount of Au NPs which can be reasonably added as 
label per cell is clearly limited, affecting the maximum 
contrast which can be obtained.
The Au NP labeling capacity of MSC is donor dependent
In order to determine the efficacy of MSC labeling with 
Au NPs at an optimized concentration of 10 nM, MSCs 
from eleven different donors were incubated with Au NP 
for 48 h. MSCs were all in passage 3 to 4, because many 
cell doublings may impair cell functioning and differenti-
ation [40]. Although the same optimized labeling strategy 
and Au NP concentration was applied, uptake of Au NPs 
varied considerably in MSCs derived from different indi-
viduals as shown in Fig. 6. Thus, other parameters apart 
from size or concentration of Au NPs must be responsi-
ble for the biologic variation in NP tolerance of MSCs, 
and testing of labeling efficiencies is mandatory for sub-
sequent in  vivo tracking experiments with NP labeled 
MSCs.
Linear MSC detection mode with ICP‑MS
Using our optimized parameters for NP-labeling of MSCs, 
we sought to determine whether MSC detection with 
ICP-MS follows a linear dose response relation. ICP-MS 
is a frequently used tool for determining bio-distributions, 
in particular of Au NPs. Upon homing, MSCs actually will 
only form a small fraction of cells on the target site. For 
a limiting dilution assay approach we were able to detect 
as little as 400 labeled MSCs  (cNP = 10 nM, 24 h) within 
Fig. 3 Cell viability of MCS exposed to ca. 4 nm core diameter 
Au NPs. Cell viability of MSCs following exposure of Au NPs. MSCs 
were exposed to various concentrations  cNP of Au NPs at different 
incubation times (24–72 h). The cell viabilities were normalized to the 
viability of cells, which had not been exposed to NPs (control media). 
Results are presented as mean value ± SD from three independent 
experiments using cells from different donors
Fig. 4 Effect of Au NP exposure on MSC in vitro proliferation and 
migration. The proliferation potential P upon exposure to Au NPs 
was normalized to that of untreated cells  (cNP = 0 nM) and those 
treated with a mitosis inhibitor. Proliferation of MSCs exposed to 
 cNP = 50 nM (24 h exposure) was significantly reduced (p < 0.05). The 
migration capacity after Au NP labeling is displayed as the ratio of 
the number of migrated cells  Nmig divided by the total cell num-
ber, which is the sum of non-migrated cells  Nnon–mig and migrated 
cells:  Ntot = Nmig + Nnon–mig. The results were normalized to that 
of untreated cells  (cNP = 0 nM) and to the negative control, where 
serum free media was used in the lower compartment. Migration of 
MSCs exposed to  cNP = 25 nM was significantly reduced (p < 0.001)
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a population of  106 acute myeloid leukemia cells (HL-60). 
Thus, cell numbers down to 400 labeled MSCs/106 HL-60 
cells are resolvable, before signal cannot be discriminated 
from the background any more. This corresponds to as 
little as 0.04% cells. The ratio between expected numbers 
of labeled cell under optimal conditions and detected 
MSC via ICP-MSC was linear (cf. Fig. 7). This allows for 
some estimation about the minimum tissue volume  Vmin 
which could be detected via homing of MSCs. In case 
one assumes a mean value  Vcell for the volume of one 
cell, the tissue volume which can be resolved would be 
 Vmin = Vcell·NMSC,limit/(NMSC/Ncell). Using the experimen-
tally determined value  NMSC,limit ≈ 400 (cf. Fig. 7) and the 
numbers  NMSC/Ncell  =  10−5 and  Vcell  =  100–1000  μm3 
[41] as example, the smallest structure which can be 
detected would be between  Vmin ≈ 0.4 and 4  mm3. This 
would be the minimum size of a tumor which could be 
detected with ICP-MS upon MSC homing with our Au 
NP approach. In summary, optimized Au NP labeling 
of MSCs and detection via ICP-MS appears suitable for 
in vivo tracking experiments.
In vivo tracking of Au NP labeled MSC
As high concentrations of Au NPs in MSCs may lead to 
impaired homing efficiency, we sought to verify whether 
the migratory capacity of MSC was preserved after Au NP 
labeling in vivo. One million human MSCs were injected 
into the tail vain of two mice per condition, respectively. 
A solution of free Au NPs and phosphate buffered saline 
(PBS) served as control. 72 h after injection the mice were 
sacrificed and the amount of Au in liver, lung, spleen, kid-
ney, and blood was determined via ICP-MS. For the con-
trol mice, the amount of detected Au was below 1 ppb and 
Fig. 5 Internalized Au NPs do not affect surface marker expression of MSCs. Representative histograms of 3 independent experiments of the 
distribution of the marker fluorescence N(Imarker) of MSC-defining surface markers of untreated MSCs (black solid line) and MSCs exposed to Au NPs 
at  cNP = 10 nM (red dashed line) for 48 h are shown. The solid grey front curve represents the isotype control
Fig. 6 Au NP uptake capacity is donor dependent. MSCs in 3rd or 4th 
passage were labeled with 10 nM Au NPs for 48 h in vitro. Internalized 
Au NPs were measured by ICP-MS, revealing considerable variations 
of Au NP uptake between eleven different MSC donors. Experiments 
were performed independent to preceding measurements. A differ-
ent batch of Au NPs was used, which was purified by ultracentrifuga-
tion instead by gel electrophoresis. Thus, absolute Au NP content as 
compared to Fig. 1 may vary
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thus below the resolution, cf. Fig. 8. The injected free Au 
NPs, but not NP labeled MSCs, accumulated predomi-
nantly in the liver, as expected from previous studies with 
similar NPs [42, 43]. The difference was significant as cal-
culated with Student’s t test (p = 0.005 and 0.04, respec-
tively). In contrast, in mice injected with Au NP labeled 
MSCs a higher amount of Au was found inside the lungs. 
However, due to very high variations (p < 0.0001 upon F 
test for equality of variances) statistical significance was 
not reached here (p = 0.2). This is in agreement with find-
ings by others, which have reported that MSCs get trapped 
in the pulmonary capillary system first, but then relocate 
into the liver or tumor/inflammation sites [44–46]. We 
conclude that in fact our optimized Au NP labeling proto-
col for human MSCs allows for proper recording the bio-
distribution of these cells. Note, that in fact some Au NPs 
associated to the MSCs could have been just adherent to 
the MSCs instead of being endocytosed. However, as the 
biodistribution of Au in case of Au NP labelled MSCs and 
plain Au NPs is different, the Au NPs must have travelled 
with the MSCs.
Discussion
On the first glance, the physical properties of Au NPs 
for MSC labeling seem well suited when looking on the 
potential perspectives for further applications in cancer 
diagnostic and therapy. For clinical applications careful 
monitoring of cellular functions is a vital prerequisite. 
After thorough testing of biological alterations in NP 
labeled MSCs we propose an optimized labeling strat-
egy for 4 nm Au NPs and human MSCs, hereby preserv-
ing migratory and proliferative capacities in  vitro and 
in vivo. While in this study we demonstrated that expo-
sure of MSCs to Au NPs at non-optimized conditions can 
have profound effects on the proliferation and migration 
behavior, the underlying molecular pathways that get dis-
turbed so far are not known. Whether inorganic NP of 
different size, shape or material require the same or other 
labeling conditions with regard to MSC biology needs 
to be determined in further studies. We have previously 
employed short tandem-repeat (STR) profiling in order 
to quantify donor cells within recipient tissue. The sen-
sitivity of this assay is about 5% [47]. Another strategy is 
fluorescent-dye based cell labeling. This method is capa-
ble to visualize MSC migration into tumors [48], however, 
quantification of light intensities in tissues is not always 
precise with regard to cell numbers. Thus, our approach 
of MSC quantification via Au NPs that is capable to detect 
0.04% labeled MSCs within unstained cells is particularly 
accurate compared to the other mentioned methods.
We additionally show that there is a remarkable vari-
ety in-between individual donors, indicating the need to 
further elucidate the mechanisms of cellular fitness with 
regard to Au NP uptake capacity. MSCs administered 
intravenously initially migrate into the lungs, while intraar-
terial administration seems to prevent this ‘first-pass’ effect 
[44–46]. However, for photothermal tumor ablation intra-
venous application strategies for Au NP carrying MSCs 
are preferred [49]. Preservation of migratory capacities of 
MSC is therefore crucial for all these strategies.
Conclusions
Tumor tropism of MSC has already been used for novel 
imaging approaches but also for cancer therapy strate-
gies. With regard to the long hike throughout the body 
Fig. 7 Linear dose dependency of MSC detection employing ICP-MS. 
 NMSC = 0–100,000 MSCs labeled with  cNP = 10 nM of Au NPs for 48 h 
were mixed with  NHL = 106 unlabeled HL-60 cells. Then, the number 
 NMSC,detect of MSCs in the mixture was determined via ICP-MS. The 
dashed line represents the expected results under optimal condi-
tions. The Au noise background level and therefore the detection 
limit was corresponding to  NMSC,limit ~ 400 labeled cells
Fig. 8 In vivo tissue distribution of MSCs labeled with Au NPs at 
concentrations of 10 and 50 nM for 48 h. Mice were injected in their 
tail vain with 50 μL of Au NP labeled MSCs (i.e.  106 cells, which had 
been incubated with 10 or 50 nM Au NPs for 48 h). Alternatively, mice 
were injected in their tail vain with 50 μL of Au NPs at a concentra-
tion of 1300 nM. After 72 h, mice were sacrificed and the amount  mAu 
of Au in the different organs was determined with ICP-MS. The data 
show the mass of Au found per mass of organ from 5 independent 
experiments (n = 5)
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towards tumor tissue and considering future applications 
in cancer therapy, MSC fitness and migration capabili-
ties appear to be of tremendous importance. We describe 
a gentle and efficient labeling strategy for human MSCs 
that is applicable in  vivo and paves the way for future 




Polymer-coated Au NPs with a core diameter of 
 dc = 4.25 ± 0.88 nm (as determined by transmission elec-
tron microscopy (TEM), in the following referred to as 
“dc = 4 nm”), a hydrodynamic diameter of  dh = 10.4 ± 0.7 
(as determined by dynamic light scattering (DLS) in 
water), and a zeta-potential of ζ = −25.1 ± 0.36 mV (as 
determined from laser doppler anemometry (LDA) in 
water) were prepared according to previously published 
protocols [30, 50]. The experimental procedure, as well 
as the effect of salt on the size and colloidal stability of 
PMA NPs, are described in detail in the Additional 
file  1. The NPs were overcoated with an amphiphilic 
polymer, poly(isobutylene-alt-maleic anhydride)-graft-
dodecylamine (PMA) [51, 52]. After synthesis, the NPs 
were purified by gel electrophoresis and by diafiltration. 
The concentration of the coated Au NPs was determined 
by UV/Vis absorption spectroscopy [53]. For detailed 
characterization of the physicochemical properties of 
these NPs we refer to previous studies [20, 53–55]. The 
Au NPs were found to be colloidally stable up to physi-
ological NaCl concentrations (see the Additional file 1).
Isolation, expansion and culture of human mesenchymal 
stem cells (MSCs)
Mesenchymal stem cells were isolated from bone pieces 
obtained from hip fragments. Dulbecco’s Modified Eagles 
Medium (DMEM, Sigma-Aldrich, #D5546) was sup-
plemented with 10% fetal bovine serum (FBS), 1% peni-
cillin/streptomycin (P/S, Sigma-Aldrich, #P4333), and 
2  mM  l-glutamine (Sigma-Aldrich, #G7513). The MCS 
were cultivated in flasks at 37 °C and 5%  CO2, until they 
reached 80% confluence. MSC where used in passages ≤5 
due to observed adverse effects on MSC functional capa-
bilities for higher passages as described previously [40].
Quantification of Au NP uptake by MSCs
The labeling efficiency of MSCs with Au NPs (ca. 4  nm 
core diameter) was examined by inductively cou-
pled plasma mass spectrometry (ICP-MS, Agilent 
7700 Series). Cells were seeded into 6-well plates (TPP, 
Switzerland, #92006) at a density of  104  MSCs/cm2 
and each well with a surface of 9  cm2 was filled with 
 Vmedium  =  3  mL of medium. Thus, in each well there 
were  Ncell = 9·104 cells. After 24 h, the growth medium 
was replaced with 1.5  mL of Au NP-containing media 
at different concentrations  (cNP  =  0–100  nM) and cells 
were incubated for 5, 24, or 48  h. After exposure, the 
cell medium was removed followed by three washing 
steps with PBS to remove non-internalized NPs. Then, 
cells were detached with 500  µL trypsin–EDTA (0.05% 
trypsin–EDTA, Thermo Fisher Scientific), collected by 
centrifugation at 280 rcf for 5 min, and washed with PBS, 
followed by an additional centrifugation step. The recov-
ered cell pellets were treated with 100 µL of lysis buffer 
(Luciferase Cell Culture Lysis Buffer, Promega, #E153A) 
for 30  min. Finally, the samples were prepared for ICP-
MS analysis by digestion in aqua regia. Hereby, 50  µL 
sample was diluted in 150  µL aqua regia, consisting of 
three parts concentrated (35  wt%) HCl (Fisher Chemi-
cal, #7647010) and one part of (67  wt%)  HNO3 (Fisher 
Chemical, #7697372), and left for digestion for at least 
3 h. The sample containing acid was diluted 1:10 in 2 wt% 
HCl prior to measuring the elemental Au concentration 
in the sample with ICP-MS. The initial cell number was 
determined by performing a Lowry protein assay (Sigma-
Aldrich, #TP0300) with the lysed cell pellets [56].
Assessment of long term labeling efficiency of MSCs 
with Au NPs by reporting exocytosis versus endocytosis
For evaluation of the long-term labeling efficiency, the 
fraction of exocytosed NPs was determined after expo-
sure to Au NPs. MSCs (adherent in 25 cm2 culture flasks) 
were exposed to  cNP =  2–100  nM of Au NPs for 24 or 
48 h. After labeling, MSCs were detached with trypsin–
EDTA, washed with PBS, and plated into new 25 cm2 cul-
ture flasks. After 24 or 48  h, the Au content remaining 
inside MSCs (i.e. the remaining endocytosed NPs) and 
present in growth medium (i.e. the exocytosed NPs) was 
determined. The intracellular Au was quantified by ICP-
MS, as described above for the quantitative uptake analy-
sis of Au NPs by MSCs. The exocytozed fraction of the 
Au NPs was determined from the Au concentration of 
the growth medium, which was diluted 1:4 in aqua regia 
first, followed by 1:10 dilution in 2 wt% HCl prior to ICP-
MS measurements. Results are represented as Au mass 
fractions of intracellular versus the intracellular + extra-
cellular Au.
Viability of MSCs labeled with Au NPs
Mesenchymal stem cells were seeded at a density of  104 
cells/well into a 96-well plate with each well filled with 
 Vmedium  =  0.1  mL of medium and exposed to Au NPs 
for 24–72 h. Then, cells were washed once with PBS and 
AlamarBlue (Thermo Fisher Scientific) was added in 
each well and incubated for desired time at 37  °C. The 
fluorescence was measured at 560  nm excitation and 
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590  nm emission wavelengths using a spectrophotom-
eter (SpectraMax 250, Molecular Devices). Cell viability 
was assumed to be proportional to the recorded fluores-
cence intensity. Results are expressed as percentage of 
cell viability V versus control (i.e. untreated cells). Experi-
ments were performed with MSCs from three independ-
ent human/MSC donors in triplicates for each time-point 
and concentration.
Proliferation of MSCs
The effect of exposure of MSCs to Au NPs on their pro-
liferation rate P was determined with carboxyfluorescein 
succinimidyl ester (CFSE) and flow cytometry (FCM). 
Cells were labeled with a certain amount of membrane-
impermeable CFSE whose fluorescent intensity decreases 
upon cell division [57]. 2.5·105  cells per sample were 
labeled with 1  µM CFSE (Molecular Probes, #C34554) 
for 10  min at 37  °C in 1  mL of PBS. Subsequently, the 
cells were washed twice with 5 mL of pre-warmed sup-
plemented DMEM and plated in 25  cm2 culture flasks. 
After 24 h NPs  (cNP = 0–50 nM) were added, and a nega-
tive control was prepared containing 5 µM of the mito-
sis inhibitor cholchicine (Sigma-Aldrich, #C9754). After 
subsequent culturing for additional 6  days, cells were 
detached with trypsin–EDTA, counter-stained with 
1  µM propidium iodide (PI, Sigma-Aldrich, #P4170), 
and signals were acquired with a BD LSR II FCM device 
with FACS Diva software (BD Biosciences). Data were 
analyzed with FlowJo version 9.5.3 (TreeStar Inc.) and 
GraphPad Prism software. CFSE was excited at 488  nm 
and emission was detected at 521  nm. Living cell were 
gated after 4′,6-diamidino-2-phenylindole (DAPI) 
(Sigma-Aldrich, #D9542) staining. Results are normal-
ized to the positive (p  =  1, no Au NPs) and negative 
control (p  =  0, cholchicine), and are representing the 
mean values ± standard deviations of the median values 
of the CFSE fluorescent intensity/cell for 3 independent 
experiments.
Migration of MSCs
The migration potential of MSCs was assessed by ana-
lyzing cell migration through membrane inserts by 
fluorescence microscopy [37]. MSCs were labeled with 
Au NPs in 25  cm2 culture flasks filled with 5 mL of 
medium at  cNP  =  0–25  nM for 2  days. Subsequently, 
cells were detached with trypsin–EDTA and trans-
ferred in serum free medium into the upper chamber 
of membrane inserts (8 µm pore size, Greiner Bio One, 
#662638), which were placed into the wells of a 24 well 
plate (Greiner Bio One, #622160). Each insert contained 
1·104 cells in  Vmedium = 0.3 mL of growth medium. The 
lower chambers were filled with growth medium con-
taining 10% humand platelet lysate (HPL, manufactured 
at the Institute for Clinical Immunology and Transfu-
sion Medicine, Giessen, Germany, in a GMP-compliant 
manner as described in Schallmoser et al. [58]) to stimu-
late MSC migration from the upper to the bottom side 
of the membrane inserts. After 16  h, cells were fixed 
with methanol and nuclei were stained with 50  µM of 
4′,6-diamidino-2-phenylindole (DAPI, Thermo Fisher 
Scientific, #D1306) for 5 min. For each sample, migrated 
and non-migrated MSCs were counted at fixed positions, 
each comprising an area of 0.38  cm2. The counting was 
based on fluorescent images acquired with a confocal 
laser scanning microscope (CLSM 510 Meta) from Zeiss 
using a Plan-Apochromat 20×/0.8 M27 objective (pin-
hole size: 1 airy unit, lateral sampling rate: 0.6 µm/pixel). 
DAPI (nuclei) was excited with a 405 nm-laser diode an 
emission was gated with a 420  nm long-pass filter. For 
imaging the inserts were placed on a microscope slide in 
a drop of PBS. For 4–6 randomly chosen positions two 
images were acquired: Non-migrated cells were captured 
by acquiring an image at a plane above the membrane, 
and migrated cells were imaged below the membrane, 
cf. the Additional file  1 for a sketch of the set-up. For 
each position (area A =  0.38  mm2) the number of cells 
above  (Nnon-mig) and below the membrane  (Nmig) was 
determined based on their nuclear staining by employing 
CellProfiler [59] and the ratio  Nmig/(Nmig + Nnon-mig) was 
calculated. Results are displayed as mean values ± stand-
ard deviations for 3 independent experiments.
Expression of surface markers of MSCs
The immunophenotype of MSCs was analyzed after 
exposure to 10  nM Au NPs for 48  h. According to the 
recommendations of the International Society for 
Cellular Therapy [38] the following surface markers 
were measured: CD14 (clone M4P9, BD Biosciences, 
#345785), CD19 (clone SJ25C1, BD, #332780), CD34 
(clone 8G12, BD, #345801), CD45 (clone 2D1, BD, 
#332784), CD73 (clone AD2, BD, #550257), CD90 (clone 
5E10, BD, #559869), CD105 (clone 266, BD, #32830) and 
HLA-DR (clone B8.12.2, Immunotech, #PNIM0463U). 
In brief, MSCs were stained for 15 min at 4 °C with flu-
orochrome-labeled monoclonal antibodies, washed with 
PBS, and resuspended in FACSFlow™ (BD, #342003) 
with 3% formaldehyde (Merck, #103999). The samples 
were measured with a LSRII FCM device with CellQuest 
Pro™ Software (both BD). Isotype-matched antibodies 
were used as negative controls (BD, #342409, #347221, 
#345818). FCS data were analyzed with FlowJo™ software 
version 9.5.3 (TreeStar Inc).
Sensitivity of MSC detection via ICP‑MS
In order to prove dose dependency of our assay, dilu-
tions of 10 nM Au NP labeled MSCs within HL-60 cells 
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were prepared.  106 of unlabeled HL-60 were diluted with 
10–0.001% labeled MSCs in increments of 10 and meas-
ured via ICP-MS. Acute promyelocytic leukemia cells 
(HL-60) were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA, USA), and were main-
tained in RPMI 1640 (Sigma-Aldrich, #R8758) supple-
mented with 10% FBS, 1% penicillin/streptomycin (P/S, 
Sigma-Aldrich, #P4333) (complete medium) at 37  °C in 
5%  CO2.
Demonstration of recording biodistributions with NP labeled 
MSCs
To evaluate the in  vivo biodistribution of NP-labeled 
MSCs, male BALB/cAJic− RAG2−/− IL-2Rgamma−/− 
mice (obtained from Prof. Dr. Dorothee von Laer; Georg-
Speyer-Haus; Johann Wolfgang Goethe-Universität 
Frankfurt) at 12–20 weeks of age were used. The experi-
ments were performed in the animal facility of the BMFZ, 
Marburg, Germany. In brief, 1 × 106 MSCs were seeded 
in T175  cm2 flasks and grown in complete cell culture 
medium. After 24 h, medium was replaced with NP con-
taining media (10 and 50 nM Au NPs). MSC were incu-
bated with Au NPs for 48 h to ensure cell labeling. After 
the desired time, the MCSs were washed three times with 
PBS, dissociated with trypsin, and resuspended in PBS. 
Subsequently, 50 μL of 1 × 106 NPs labeled MSCs were 
injected in a tail vein of mice. Additionally, a group of 
Mice were injected with 50 μL of pure Au NPs at a con-
centration of 1300 nM. Mice injected with PBS were used 
as control. 72 h post injection, the mice were sacrificed, 
and the amount of Au in the lung, liver, spleen, kidney, 
and blood was evaluated by the ICP-MS. For the control 
mice group, the Au detected was below 1 ppb and thus 
below the resolution. Data shown represent an average of 
n = 5 independent experiments.
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